NEW YORK (GenomeWeb) – Molecular Stethoscope announced today the completion of an $8.2 million seed financing, which will enable the company to continue developing its liquid biopsy tests for cardiometabolic and neurodegenerative diseases.

Additionally, the company has signed a two-year research collaboration agreement with Pfizer to develop a blood-based assay that can identify subjects at critical stages of disease progression in key cardiometabolic conditions.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.